Panpan Liu

16PUBLICATIONS
25CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 28, 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Yuchen Zhang, Man Nie, Yi Cao

|May 29, 2025
Cardiomyocyte-localized CCDC25 senses NET DNA to promote doxorubicin cardiotoxicity by activating autophagic flux.

Man Nie, Dexin Lei, Zhou Liu

|May 03, 2025
Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial.

Qihua Zou, Yuchen Zhang, Hui Zhou

|Oct 07, 2024
HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2.

Panpan Liu, Yao Luo, Hongyu Wu

|Apr 24, 2024
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Jiang-Jiang Li, Tiantian Yu, Peiting Zeng

|Oct 27, 2022
Developing Bi-Gold Compound BGC2a to Target Mitochondria for the Elimination of Cancer Cells.

Qingbin Cui, Wenwen Ding, Panpan Liu

Pageof 3

Frequent Collaborators

5 joint publications

Zhiming Li

5 joint publications

Qingqing Cai

4 joint publications

Peng Huang

3 joint publications

Shijun Wen